Q1 2026 Recap: Top FDA Approvals HCPLive Innovative Biologics Expected Biologic Drug Approvals in 2026 Public Meeting: FDA Rare Disease Day 2026 02 23 2026 FDA FDA Category 2 Update: The 5 Peptides Still Facing Heavy Review As excitement builds around peptides potentially moving off the FDA Category 2 list, it's important to understand one key reality: Not A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are